Successful Treatment of Severe Purpura Fulminans With Anakinra.

Abstract

Purpura fulminans (PF) is a rare, often fatal pediatric condition characterized by intravascular thrombosis and hemorrhagic infarction of the skin. A timely diagnosis and treatment are paramount to prevent the involvement of internal organs, causing disseminated intravascular coagulation and gangrene of the extremities. The management of PF requires a comprehensive approach, including the treatment of the underlying infection, anticoagulation, and anti-inflammatory therapy. Herein we present the case of a child with severe PF successfully treated with anakinra, an anti-IL1-receptor monoclonal antibody.